For instance, in a phase III randomized-controlled, double-blinded trial with stage III non-small-cell lung cancer patients undergoing chemoradiotherapy, the addition of durvalumab (anti-PDL1 antibody) showed a significant increase in progression-free survival (198). Here, CD274 is linked to non-small cell lung carcinoma.